Actively Recruiting
Evaluation of the Pathobiology of CALR-mutated MPN Cells
Led by Wake Forest University Health Sciences · Updated on 2026-02-25
35
Participants Needed
2
Research Sites
84 weeks
Total Duration
On this page
Sponsors
W
Wake Forest University Health Sciences
Lead Sponsor
A
Atrium Health Levine Cancer Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
CONDITIONS
Official Title
Evaluation of the Pathobiology of CALR-mutated MPN Cells
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written (or electronic) informed consent and HIPAA authorization for release of personal health information by participant or his/her legally authorized representative (LAR).
- Age 2518 years at the time of enrollment
- Diagnosis of myeloproliferative neoplasm (MPN) according to 2022 World Health Organization classification of MDS/MPNs
- CALR-positive genetic mutation
You will not qualify if you...
- Diagnosis of MPN with JAK2 V617F mutation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Atrium Health Levine Cancer
Charlotte, North Carolina, United States, 28204
Actively Recruiting
2
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157
Actively Recruiting
Research Team
C
Courtney Schepel
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here